Omnicell Inc (OMCL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OMCL SEC filings page.
Omnicell Inc (OMCL) reported $1.2B in revenue over the twelve months to Jun 30, 2026, up 8.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue recovered in FY2025, but thin operating margins and weaker cash conversion show a business still absorbing substantial operating costs.
FY2025 net income was$2.1M against$127M of operating cash flow, so reported earnings materially understate cash produced in the period. Yet operating cash flow and free cash flow both declined from FY2024 while gross margin held near42% and operating margin stayed below1% , pointing to cash benefits that are not translating into operating profitability.
Revenue rebounded in FY2025, but operating margin reached only
Liabilities fell materially from FY2023 to FY2025 as debt-to-equity declined from 0.9x to 0.6x, indicating a less leveraged balance sheet. FY2025 financing cash flow was
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Omnicell Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Omnicell Inc has an operating margin of 0.4%, meaning the company retains less than $1 of operating profit per $100 of revenue. This below-average margin results in a low score of 27/100, suggesting thin profitability after operating expenses. This is up from 0.0% the prior year.
Omnicell Inc's revenue grew 6.5% year-over-year to $1.2B, a solid pace of expansion. This earns a growth score of 36/100.
Omnicell Inc has a moderate D/E ratio of 0.60. This balance of debt and equity financing earns a leverage score of 57/100.
Omnicell Inc's current ratio of 1.43 indicates adequate short-term liquidity, earning a score of 38/100. The company can meet its near-term obligations, though with limited headroom.
Omnicell Inc converts 7.3% of revenue into free cash flow ($86.9M). This strong cash generation earns a score of 66/100.
Omnicell Inc generates a 0.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 27/100. This is down from 1.0% the prior year.
Omnicell Inc scores 2.24, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($1.5B) relative to total liabilities ($742.9M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Omnicell Inc passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Omnicell Inc reported $2.1M of net income while generating $127.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead.
Key Financial Metrics
Earnings & Revenue
Omnicell Inc generated $312.2M in revenue in Q2 2026. This represents an increase of 7.4% from the same quarter a year earlier. Against the prior quarter it is up 0.8%.
Omnicell Inc's EBITDA was $51.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 84.9% from the same quarter a year earlier. Against the prior quarter it is up 44.7%.
Omnicell Inc reported $24.3M in net income in Q2 2026. This represents an increase of 330.7% from the same quarter a year earlier. Against the prior quarter it is up 113.8%.
Omnicell Inc earned $0.52 per diluted share (EPS) in Q2 2026. This represents an increase of 333.3% from the same quarter a year earlier. Against the prior quarter it is up 108.0%.
Cash & Balance Sheet
Omnicell Inc generated $59.4M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 91.7% from the same quarter a year earlier. Against the prior quarter it is up 41.1%.
Omnicell Inc held $292.2M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Omnicell Inc's gross margin was 49.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 5.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.7 percentage points.
Omnicell Inc's operating margin was 10.4% in Q2 2026, reflecting core business profitability. This is up 7.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.
Omnicell Inc's net profit margin was 7.8% in Q2 2026, showing the share of revenue converted to profit. This is up 5.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.1 percentage points.
Omnicell Inc's ROE was 1.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Capital Allocation
Omnicell Inc invested $20.3M in research and development in Q2 2026. This represents a decrease of 5.9% from the same quarter a year earlier. Against the prior quarter it is down 5.7%.
Omnicell Inc invested $8.9M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 24.1% from the same quarter a year earlier. Against the prior quarter it is down 28.1%.
Not reported for Q2 2026.
OMCL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $312.2M+7.4% | $309.9M+14.9% | $314.0M+2.3% | $310.6M+10.0% | $290.6M+5.0% | $269.7M+9.6% | $306.9M+18.6% | $282.4M-5.4% |
| Cost of Revenue | $159.3M-2.2% | $169.5M+6.8% | $183.7M+11.2% | $176.1M+10.0% | $162.9M+0.3% | $158.7M+3.4% | $165.1M+7.6% | $160.2M-3.9% |
| Gross Profit | $152.9M+19.8% | $140.4M+26.5% | $130.3M-8.1% | $134.5M+10.0% | $127.7M+11.7% | $110.9M+19.8% | $141.8M+34.5% | $122.3M-7.3% |
| R&D Expenses | $20.3M-5.9% | $21.5M+4.8% | $22.6M-13.4% | $24.0M+13.2% | $21.6M+2.2% | $20.5M-6.9% | $26.0M-2.9% | $21.2M-12.6% |
| SG&A Expenses | $100.2M+2.2% | $102.0M0.0% | $107.4M+3.9% | $102.2M+8.2% | $98.0M+8.8% | $102.0M+10.4% | $103.3M+1.3% | $94.5M-9.1% |
| Operating Income | $32.4M+299.6% | $16.9M+245.1% | $415K-96.7% | $8.2M+25.6% | $8.1M+151.9% | -$11.6M+46.8% | $12.4M+153.1% | $6.6M+76.8% |
| EBITDA | $51.2M+84.9% | $35.4M+322.9% | $20.2M-37.6% | $27.6M+3.3% | $27.7M+15.4% | $8.4M+1510.1% | $32.4M+151.4% | $26.8M+47.8% |
| Income Tax | $9.5M+98.3% | $5.5M+321.3% | $2.7M-64.9% | $4.2M+41.5% | $4.8M+7.9% | -$2.5M-16.3% | $7.8M+287.3% | $3.0M+63.9% |
| Net Income | $24.3M+330.7% | $11.4M+261.7% | -$2.0M-112.8% | $5.5M-36.7% | $5.6M+51.0% | -$7.0M+55.2% | $15.8M+210.2% | $8.6M+55.4% |
| EPS (Basic) | $0.53+341.7% | $0.25+266.7% | -$0.05-114.7% | $0.12-36.8% | $0.12+50.0% | -$0.15+55.9% | $0.34+206.3% | $0.19+58.3% |
| EPS (Diluted) | $0.52+333.3% | $0.25+266.7% | -$0.05-114.7% | $0.12-36.8% | $0.12+50.0% | -$0.15+55.9% | $0.34+206.3% | $0.19+58.3% |
| Diluted Shares (Avg) | 46M-1.5% | 46M-1.4% | N/A | 46M-1.1% | 47M+2.1% | 47M+1.9% | N/A | 46M+1.8% |
Not reported in any period shown, so not listed: Interest Expense.
OMCL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.0B-6.8% | $2.0B-6.8% | $2.0B-6.9% | $1.9B-15.4% | $2.1B-6.4% | $2.2B-5.8% | $2.1B-4.8% | $2.3B+3.7% |
| Current Assets | $735.4M-12.9% | $722.3M-14.0% | $680.1M-16.6% | $659.6M-34.8% | $844.8M-15.2% | $839.7M-15.2% | $815.5M-12.1% | $1.0B+10.7% |
| Cash & Equivalents | $292.2M-26.8% | $239.2M-38.2% | $196.5M-46.8% | $180.1M-68.4% | $399.0M-28.3% | $386.8M-24.5% | $369.2M-21.1% | $570.6M+27.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $96.7M-8.6% | $99.2M+8.8% | $100.9M+13.8% | $107.4M+13.0% | $105.8M+13.4% | $91.1M-11.9% | $88.7M-19.5% | $95.1M-18.2% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $737.2M-0.2% | $737.3M+0.2% | $737.9M+0.4% | $737.9M+0.1% | $738.5M+0.4% | $736.0M+0.1% | $734.7M-0.1% | $737.2M+0.4% |
| Total Liabilities | $707.3M-19.8% | $747.5M-16.4% | $742.9M-15.4% | $727.7M-32.1% | $881.9M-19.0% | $894.4M-18.3% | $877.6M-15.4% | $1.1B+3.7% |
| Current Liabilities | $447.4M-24.7% | $483.0M-20.5% | $476.6M-20.0% | $456.6M-52.5% | $594.4M+46.0% | $607.5M+45.9% | $595.7M+62.0% | $961.5M+160.3% |
| Non-Current Liabilities | $259.8M-9.6% | $264.4M-7.8% | $266.3M-5.6% | $271.1M+144.8% | $287.5M-57.8% | $286.8M-57.7% | $282.0M-57.9% | $110.7M-83.3% |
| Total Equity | $1.3B+2.2% | $1.3B0.0% | $1.2B-0.9% | $1.2B-0.8% | $1.3B+5.1% | $1.3B+5.8% | $1.2B+4.6% | $1.2B+3.7% |
| Retained Earnings | $420.6M+10.2% | $396.3M+5.4% | $384.9M+0.5% | $387.0M+5.4% | $381.5M+6.4% | $375.9M+6.0% | $382.9M+3.4% | $367.0M-4.6% |
Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt.
OMCL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $68.3M+59.8% | $54.5M+110.2% | $30.4M-46.1% | $28.3M+24.2% | $42.8M-27.2% | $25.9M-48.1% | $56.3M+46.6% | $22.8M-60.1% |
| Depreciation & Amortization | $18.8M-4.1% | $18.6M-7.1% | $19.8M-0.8% | $19.4M-4.0% | $19.6M-5.8% | $20.0M-5.9% | $20.0M-8.1% | $20.2M+40.3% |
| Stock-Based Compensation | $12.2M+15.9% | $9.5M-11.9% | N/A | $11.2M-3.4% | $10.5M+5.0% | $10.8M+24.8% | N/A | $11.6M-22.5% |
| Capital Expenditures | $8.9M-24.1% | $12.4M+11.3% | $7.7M-15.2% | $9.8M+10.0% | $11.8M+23.3% | $11.2M+24.7% | $9.1M+0.2% | $8.9M-16.6% |
| Free Cash Flow | $59.4M+91.7% | $42.1M+185.1% | $22.6M-52.1% | $18.5M+33.3% | $31.0M-37.0% | $14.8M-64.0% | $47.2M+60.9% | $13.9M-70.1% |
| Investing Cash Flow | -$12.5M+21.3% | -$15.9M-0.8% | -$14.4M-6.3% | -$14.3M-7.1% | -$15.9M-17.5% | -$15.7M-27.5% | -$13.6M-9.7% | -$13.3M+6.0% |
| Financing Cash Flow | -$23.4M-103.8% | $2.4M-40.8% | $9.1M+103.9% | -$220.0M-6289.7% | -$11.5M+31.0% | $4.0M-66.1% | -$234.4M-1885.5% | $3.6M+25.8% |
| Share Buybacks | N/A | N/A | $0 | $61.9M | N/A | N/A | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
OMCL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.0%+5.0pp | 45.3%+4.2pp | 41.5%-4.7pp | 43.3%0.0pp | 43.9%+2.6pp | 41.1%+3.5pp | 46.2%+5.5pp | 43.3%-0.9pp |
| Operating Margin | 10.4%+7.6pp | 5.4%+9.8pp | 0.1%-3.9pp | 2.6%+0.3pp | 2.8%+1.6pp | -4.3%+4.6pp | 4.0%+13.1pp | 2.3%+1.1pp |
| Net Margin | 7.8%+5.8pp | 3.7%+6.3pp | -0.7%-5.8pp | 1.8%-1.3pp | 1.9%+0.6pp | -2.6%+3.8pp | 5.2%+10.7pp | 3.1%+1.2pp |
| Return on Equity | 1.9%+1.4pp | 0.9%+1.5pp | -0.2%-1.4pp | 0.4%-0.3pp | 0.4%+0.1pp | -0.6%+0.8pp | 1.3%+2.5pp | 0.7%+0.2pp |
| Return on Assets | 1.2%+1.0pp | 0.6%+0.9pp | -0.1%-0.9pp | 0.3%-0.1pp | 0.3%+0.1pp | -0.3%+0.4pp | 0.8%+1.4pp | 0.4%+0.1pp |
| Current Ratio | 1.64+0.2x | 1.50+0.1x | 1.43+0.1x | 1.44+0.4x | 1.42-1.0x | 1.38-1.0x | 1.37-1.2x | 1.05-1.4x |
| Debt-to-Equity | 0.55-0.2x | 0.59-0.1x | 0.60-0.1x | 0.60-0.3x | 0.70-0.2x | 0.71-0.2x | 0.71-0.2x | 0.870.0x |
| Asset Turnover | 0.160.0x | 0.150.0x | 0.160.0x | 0.160.0x | 0.140.0x | 0.130.0x | 0.140.0x | 0.120.0x |
| FCF Margin | 19.0%+8.4pp | 13.6%+8.1pp | 7.2%-8.2pp | 6.0%+1.0pp | 10.7%-7.1pp | 5.5%-11.2pp | 15.4%+4.1pp | 4.9%-10.6pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Omnicell Inc OMCL | FY2025 | $1.2B | $2.1M | 0.2% | $1.5B | 42/100 |
| Phreesia, Inc. PHR | FY2026 | $480.6M | $2.3M | 0.5% | $625.1M | 45/100 |
| Certara, Inc. CERT | FY2025 | $418.8M | -$1.6M | -0.4% | $1.4B | 51/100 |
| GoodRx Holdings, Inc. GDRX | FY2025 | $796.9M | $30.4M | 3.8% | $1.1B | 56/100 |
| 10x Genomics, Inc. TXG | FY2025 | $642.8M | -$43.5M | -6.8% | $12.2B | 72/100 |
| Schrodinger, Inc. SDGR | FY2025 | $255.9M | -$103.3M | -40.4% | $2.3B | 60/100 |
Where Omnicell Inc Ranks
Frequently Asked Questions
What is Omnicell Inc's annual revenue?
Omnicell Inc (OMCL) reported $1.2B in total revenue for fiscal year 2025. This represents a 6.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Omnicell Inc's revenue growing?
Omnicell Inc (OMCL) revenue grew by 6.5% year-over-year, from $1.1B to $1.2B in fiscal year 2025.
Is Omnicell Inc profitable?
Yes, Omnicell Inc (OMCL) reported a net income of $2.1M in fiscal year 2025, with a net profit margin of 0.2%.
What is Omnicell Inc's EBITDA?
Omnicell Inc (OMCL) had EBITDA of $84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Omnicell Inc's gross margin?
Omnicell Inc (OMCL) had a gross margin of 42.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Omnicell Inc's operating margin?
Omnicell Inc (OMCL) had an operating margin of 0.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Omnicell Inc's net profit margin?
Omnicell Inc (OMCL) had a net profit margin of 0.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Omnicell Inc's return on equity (ROE)?
Omnicell Inc (OMCL) has a return on equity of 0.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Omnicell Inc's free cash flow?
Omnicell Inc (OMCL) generated $86.9M in free cash flow during fiscal year 2025. This represents a -42.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Omnicell Inc's operating cash flow?
Omnicell Inc (OMCL) generated $127.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Omnicell Inc's total assets?
Omnicell Inc (OMCL) had $2.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Omnicell Inc's capital expenditures?
Omnicell Inc (OMCL) invested $40.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Omnicell Inc spend on research and development?
Omnicell Inc (OMCL) invested $88.7M in research and development during fiscal year 2025.
What is Omnicell Inc's current ratio?
Omnicell Inc (OMCL) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.
What is Omnicell Inc's debt-to-equity ratio?
Omnicell Inc (OMCL) had a debt-to-equity ratio of 0.60 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Omnicell Inc's return on assets (ROA)?
Omnicell Inc (OMCL) had a return on assets of 0.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Omnicell Inc's P/E ratio?
Omnicell Inc (OMCL) trades at 39.2x earnings, its market capitalization divided by net income of $39.1M net income, trailing 12 months to June 30, 2026. The market capitalization is $1.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Omnicell Inc's price-to-sales ratio?
Omnicell Inc (OMCL) trades at 1.2x sales, its market capitalization divided by revenue of $1.2B revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.5B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Omnicell Inc's Altman Z-Score?
Omnicell Inc (OMCL) has an Altman Z-Score of 2.24, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Omnicell Inc's Piotroski F-Score?
Omnicell Inc (OMCL) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Omnicell Inc's earnings high quality?
Omnicell Inc (OMCL) reported $2.1M of net income while generating $127.3M in operating cash flow. The ratio between the two is outside the range this page publishes as a per-dollar figure, so both figures are given instead. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Omnicell Inc?
Omnicell Inc (OMCL) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.